The evolution of patenting in the life sciences: Where have we come from and where are we going?
The Centre for Intellectual Property Policy welcomes S. Serge Shahinian, Patent Agent and Partner, Goudreau Gage Dubuc.
Abstract
Thomas Jefferson, when drafting the definition of a patentable 鈥渋nvention鈥� in 1793 (which persists today in slightly modified form), was likely unaware that someday inventors would be seeking patent protection for genes and proteins, therapeutic and diagnostic applications, and living material such as genetically-modified cells, plants and animals. It is for this reason that the interpretation of what constitutes patentable subject matter is under constant evolution as new technologies are developed in the life sciences. Examples shall be discussed of how the courts have interpreted such issues up to present day, in an effort to assess trends and the future of patenting in the life sciences.
About the speaker
Serge Shahinian is a Patent Agent and Partner with the intellectual property firm Goudreau Gage Dubuc. He has been practicing in the intellectual property field since 2000, following prior doctoral and post-doctoral training in biochemistry and biology. His practice covers a wide range of technologies in the life sciences, including biotechnology, and pharmaceutical and chemical technologies. His practice includes the procurement of patent rights in domestic and foreign jurisdictions, as well as opinions and counseling in patentability, validity and infringement matters.
A request for accreditation has been made to the Barreau du Qu茅bec for 1.5 hours of Continuing Legal Education.
